Clinical trials: Plaque Psoriasis.
Plaque Psoriasis
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis.
This study will evaluate the effects of an experimental (being tested) study drug called apremilast. Apremilast works by lowering some of the chemicals that affect psoriasis and therefore improves the symptoms of psoriasis.
- Trial name
- ESTEEM 2 (NCT01232283)
- Testing
- Apremilast, Topical or Phototherapy Therapy
- Where
- 46 sites in United States, Austria and 7 more
- Volunteers
- 413 people
- Sponsor
- Amgen
Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis
A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)
Primary purpose of the study is to assess the concentration of bimekizumab in mature human breast milk.
- Conditions
- Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Axial Spondyloarthritis, Hidradenitis Suppurativa
- Trial name
- BE CARING (NCT06888193)
- Testing
- Bimekizumab
- Where
- 14 sites in United States, Canada and 3 more
- Volunteers
- 20 people
- Sponsor
- UCB Biopharma SRL
Psoriasis, Parapsoriasis
A Study of the Safety and Effectiveness of Infliximab in Patients With Plaque-type Psoriasis
The purpose of the study is to evaluate the safety and effectiveness of scheduled and as needed treatment of psoriasis with infliximab.
- Trial name
- NCT00106847
- Testing
- Infliximab
- Volunteers
- 683 people
- Sponsor
- Centocor, Inc.
Psoriasis
Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque Psoriasis
The main objective of this study is to evaluate the efficacy and safety of risankizumab compared with secukinumab for the treatment of adult subjects with moderate to severe plaque psoriasis who are candidates for systemic…
- Trial name
- NCT03478787
- Testing
- risankizumab, secukinumab
- Where
- 61 sites in United States, Canada and 7 more
- Volunteers
- 327 people
- Sponsor
- AbbVie
Plaque Psoriasis
A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis
The main purpose of this study is to evaluate the efficacy of the study drug ixekizumab compared to ustekinumab in participants with moderate-to-severe-plaque psoriasis.
- Trial name
- IXORA-S (NCT02561806)
- Testing
- Ixekizumab, Ustekinumab
- Where
- 48 sites in Austria, Belgium and 11 more
- Volunteers
- 302 people
- Sponsor
- Eli Lilly and Company
Moderate-to-severe Chronic Plaque Psoriasis
Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis
An open label study to investigate the safety and efficacy of ponesimod in participants with moderate-to-severe chronic plaque psoriasis
- Trial name
- NCT07362017
- Testing
- Ponesimod
- Where
- 10 sites in United States
- Volunteers
- 300 people
- Sponsor
- Vanda Pharmaceuticals
Psoriasis, Skin Diseases
A Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Moderate to Severe Plaque Psoriasis
This is a randomized, double-blind, placebo-controlled, multicenter phase III clinical study to evaluate the efficacy and safety of AK111 in the treatment of subjects with moderate to severe plaque psoriasis.
- Trial name
- NCT06066125
- Testing
- AK111
- Where
- 34 sites in China
- Volunteers
- 351 people
- Sponsor
- Akeso
Psoriasis
Double-Blind, Randomized, Placebo-controlled Comparison of CC-10004 in Subjects With Moderate to Severe Plaque Type Psoriasis
There is an unmet medical need for safe, effective oral therapy for moderate-to-severe psoriasis. CC-10004 will be evaluated in a controlled setting of a clinical study.
- Trial name
- PSOR-003 (NCT00606450)
- Testing
- CC-10004
- Where
- 31 sites in Canada, Czechia and 1 more
- Volunteers
- 260 people
- Sponsor
- Amgen
Psoriasis
A Phase 3 Study in Participants With Moderate to Severe Psoriasis
This study will assess the safety and efficacy of LY2439821 compared to placebo in participants with moderate to severe, chronic plaque psoriasis.
- Trial name
- UNCOVER-1 (NCT01474512)
- Testing
- 80 mg Ixekizumab Dosing Regimens 1, 2, and 3
- Where
- 104 sites in United States, Australia and 9 more
- Volunteers
- 1,296 people
- Sponsor
- Eli Lilly and Company
Psoriasis
A Safety Study of Ustekinumab in the Treatment of Pediatric Participants Aged 6 Years and Older With Moderate to Severe Plaque Psoriasis
The purpose of this study is to monitor the long-term safety of ustekinumab in pediatric participants (6 years to 17 years of age at the time of inclusion) with moderate to severe plaque psoriasis, through monitoring for the…
- Trial name
- STELARA (NCT03218488)
- Testing
- Ustekinumab
- Where
- 30 sites in Austria, Belgium and 9 more
- Volunteers
- 135 people
- Sponsor
- Janssen-Cilag International NV
Plaque Psoriasis
Efficacy and Tolerability of Enstilar® in Daily Practice
This study aims to assess how the Enstilar® aerosol foam performs in daily real-life practice with regards to effectiveness and convenience of application to psoriasis plaques on body and extremities.
- Trial name
- NCT02881346
- Testing
- Enstilar®
- Where
- Germany
- Volunteers
- 410 people
- Sponsor
- LEO Pharma
Psoriasis
A Study of GSK2981278 Ointment in Subjects With Plaque Psoriasis
GSK2981278 is an inverse agonist of retinoic acid receptor-related orphan receptor (ROR) gamma. The aim of this study is to evaluate the safety, tolerability, clinical effect, and systemic exposure potential of topically applied…
- Trial name
- NCT03004846
- Testing
- GSK2981278 ointment, Vehicle ointment
- Where
- Germany
- Volunteers
- 8 people
- Sponsor
- GlaxoSmithKline
Psoriasis Vulgaris
A Psoriasis Plaque Test Comparing Products for the Treatment of Psoriasis Vulgaris
The purpose of this trial is to compare the anti-psoriatic effect of a topical combination product containing clobetasol propionate and calcipotriol in an ointment formulation to the single components in the same vehicle using a…
- Trial name
- NCT01043224
- Testing
- Combination of clobetasol propionate plus calcipotriol ointment, clobetasol propionate ointment, calcipotriol ointment, and the ointment vehicle
- Where
- France
- Volunteers
- 24 people
- Sponsor
- LEO Pharma
Chronic Plaque Psoriasis
Observational Study of Patients With Moderate to Severe Chronic Plaque Psoriasis
This study will assess the use of risankizumab in adult patients with moderate to severe chronic plaque psoriasis and compare risankizumab to other commonly used biologics.
- Trial name
- VALUE (NCT03982394)
- Where
- 302 sites in Argentina, Australia and 19 more
- Volunteers
- 2,759 people
- Sponsor
- AbbVie
Plaque Psoriasis
A Randomized Double Blind Vehicle Controlled Dose Ranging Parallel Design Multiple Site Clinical Study
The objectives of this study are to evaluate the therapeutic efficacy and safety of DSXS and a Placebo in patients with moderate to severe scalp psoriasis.
- Trial name
- NCT02413229
- Testing
- DSXS1411
- Volunteers
- 151 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Psoriasis
A Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp
This is a Phase 3, multicenter, randomized, placebo-controlled, double-blind study of the efficacy and safety of apremilast (CC-10004) in subjects with moderate to severe plaque psoriasis of the scalp.
- Trial name
- STYLE (NCT03123471)
- Testing
- Apremilast
- Where
- 45 sites in United States, Canada
- Volunteers
- 303 people
- Sponsor
- Amgen
Psoriasis, Atopic Dermatitis
Multiple Ascending-Dose Study of XmAb®27564 in Patients With Psoriasis or Atopic Dermatitis
The purpose of this study is to evaluate the safety and tolerability of XmAb27564 following multiple doses among participants with plaque psoriasis and atopic dermatitis.
- Trial name
- NCT06005792
- Testing
- XmAb27564
- Where
- 7 sites in United States, Canada
- Volunteers
- 23 people
- Sponsor
- Xencor, Inc.
Moderate to Severe Plaque Psoriasis
Documentation of Humira in Psoriasis Patients in Routine Clinical Practice
Safety and Effectiveness of adalimumab (Humira) in Psoriasis Patients in Routine Clinical Practice.
- Trial name
- LOTOS (NCT01077232)
- Where
- 641 sites in Germany
- Volunteers
- 5,442 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Psoriasis Vulgaris, Psoriatic Arthritis
A Phase 3 Clinical Study of KHK 4827
This study is designed to evaluate the safety and efficacy of long-term exposure to KHK4827 in subjects with plaque psoriasis (psoriasis vulgaris, psoriatic erythroderma) who have completed Study 4827-003 (Study 003)and in…
- Conditions
- Psoriasis Vulgaris, Psoriatic Arthritis, Pustular; Psoriasis, Palmaris Et Plantaris, Psoriatic Erythroderma
- Trial name
- NCT02052609
- Testing
- KHK4827 140mg SC, KHK4827 210mg SC
- Where
- Japan
- Volunteers
- 155 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Psoriasis
A Study of the Early Activity of Ixekizumab (LY2439821) in Moderate-to-Severe Psoriasis
To detect onset of activity of ixekizumab in participants with moderate-to-severe plaque psoriasis and to document the same using sequential photographic images.
- Trial name
- NCT02387801
- Testing
- Ixekizumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Eli Lilly and Company